Developing novel gene therapy technology for treatment of glycine encephalopathy (360G-Wellcome-210774_Z_18_Z)

£365,837

"Glycine encephalopathy, also known as non-ketotic hyperglycinaemia (NKH), is a life limiting inherited neuro-metabolic disease which presents soon after birth and leads to severe neurological outcomes including epilepsy and profound developmental delay. Current treatments for NKH are neither effective long-term, nor curative. Glycine encephalopathy is characterized by accumulation of glycine and is known to result from mutation of genes that encode the glycine cleavage system so that glycine cannot be broken down. The majority of affected children carry mutations in GLDC, encoding glycine decarboxylase. In this project we aim to develop gene therapy for glycine encephalopathy to restore GLDC function in the liver using lentiviral vector to provide permanent delivery of the therapeutic sequence. In a glycine encephalopathy model we will test a novellentiviral vector that offers enhanced safety and performance. This will be a key step towards potential clinical implementation of this therapy

Where is this data from?

This data was originally published by The Wellcome Trust. If you need to report a problem in the data please contact The Wellcome Trust directly, see their GrantNav publisher page for more information.

Grant Details

Amount Awarded 365837
Applicant Surname Greene
Approval Committee Innovator Awards Advisory Group
Award Date 2018-09-15T00:00:00+00:00
Financial Year 2017/18
Grant Programme: Title Innovator Award
Internal ID 210774/Z/18/Z
Lead Applicant Prof Nicholas Greene
Other Applicant(s) Dr John Counsell
Partnership Value 365837
Planned Dates: End Date 2021-12-31T00:00:00+00:00
Planned Dates: Start Date 2018-08-31T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Greater London